Develops sodium thiosulfate injections for cancer patients.
Jun 2026Revenue $59.2M/yrExpenses $60.3M/yr
No trendCash runway over 10 years from Jun 2026
Figures by year
When will Fennec Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $59.2M and expenses $60.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $44.6M | $50.9M | −$6.28M |
| Dec 2024 | $47.5M | $45.0M | $2.57M |
| Dec 2023 | $21.3M | $34.0M | −$12.8M |
| Dec 2022 | $1.53M | $24.1M | −$22.6M |
| Dec 2020 | $170K | $18.1M | −$17.9M |
| Dec 2019 | $0.00 | $13.0M | −$13.0M |
| Dec 2018 | $0.00 | $10.4M | −$10.4M |
| Dec 2017 | $0.00 | $6.95M | −$6.95M |
| Dec 2016 | $0.00 | $2.87M | −$2.87M |
| Dec 2015 | $0.00 | $1.89M | −$1.89M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.